Law360, New York (March 02, 2011, 1:57 PM ET) -- A Clinical Data Corp. shareholder filed a putative class action Tuesday in Delaware against the drug company’s board of directors in an attempt to halt its $1.2 billion acquisition by Forest Laboratories Inc., saying the bid grossly undervalues the company.
The proposed acquisition would result in a sale price of $30 per share plus up to $6 per share in contingent consideration if the company’s antidepressant Viibryd, recently approved by the U.S. Food and Drug Administration, meets certain sales benchmarks, according to a complaint filed by...
Shareholder Seeks To Halt $1.2B Clinical Data Sale
To view the full article, take a free trial now.
